Quantitative method to identify the source of hepatitis B surface antigen

Case ID:
C17133

Unmet Need / Invention Novelty: Loss of hepatitis B surface antigen (HBsAg) is defined as a functional cure for chronic hepatitis B virus infection, but it is clinically challenged by the derivation of HBsAg from two sources that must be uniquely targeted: covalently closed circular DNA (cccDNA) and integrated HBV DNA (iDNA). Currently, no rapid method exists to distinguish the sources of HBsAg in patients with chronic hepatitis B (CHB). There is critical need for a method to rapidly and accurately identify the source of the HBsAg from liver tissue to help clinicians or clinical trial designers to subtype patients and choose appropriate therapeutics to maximize the likelihood of HBsAg loss.

 

Technical Details: Johns Hopkins researchers have developed a method to identify the source(s) of hepatitis B surface antigen (HBsAg) from liver tissue. The method consists of a sensitive and specific multiplex droplet digital PCR that characterizes the relative amounts of HBsAg that derive from cccDNA and/or iDNA, as indicators of responsiveness to treatments and patient outcome. Proof-of-concept studies using liver tissues from patients infected with hepatitis B, demonstrated a patient-specific enrichment of cccDNA or iDNA-derived transcripts . This evidence strongly supports that the technology can be used to stratify patients based on their predominant source of HBsAg.

 

Value Proposition:

·      Simple and quantitative method to identify the source of HBsAg

·      Requires small amounts of liver tissue from liver biopsy

·      Specific and precise distinction between cccDNA and iDNA derived HBsAg

·      Permits subtype specific and appropriate therapeutic selection from emerging therapeutics

 

Looking for Partners to: Develop & commercialize the technology as a prognostic tool for estimating treatment response, and a monitoring tool to improve patient outcomes based on the source of HBsAg in human clinical samples.

 

Stage of Development: Pre-clinical

                                                               

Data Availability: Ex-vivo including proof-of-concept with clinical samples

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
PAN-GENOTYPIC ASSAY AND RELATED ASPECTS FOR THE QUANTITATIVE IDENTIFICATION OF cccDNA-DERIVED OR INTEGRATED DNA-DERIVED HEP HEPATITIS B SURFACE ANTIGEN PCT: Patent Cooperation Treaty United States 18/835,397   8/2/2024     Pending
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum